🔗 Share this article

As the US undertakes sweeping revisions to its vaccination guidelines, an unexpected name has emerged somewhat surprisingly: Tracy Beth Høeg, an American of Danish descent sports medicine doctor and public health researcher who first made her name by expressing skepticism about Covid vaccines during the global health crisis and has focused upon potential fatalities following COVID-19 vaccination in her recent tenure at the FDA.

Scheduled Overhauls to Pediatric Immunization Program

Health officials planned to announce major changes to the childhood immunization program recently, aligning the US with the Danish vaccine program, it is understood – a major change that would put the US at odds with a large portion of the international standard with insufficient data for improved outcomes. The announcement has been postponed until the new year.

Rather than the director of the vaccine center, Dr. Høeg is set to speak at the event. She was just designated acting director of the FDA’s CDER, the fifth appointee to lead the center this calendar year.

Consolidating Power at the Agency

Høeg's temporary position could signify a closer partnership between the pharmaceutical and biologics centers as Dr. Høeg and Prasad consolidate power at the agency – and it points to a greater focus upon dismantling already-approved immunizations at the FDA.

Dr. Høeg has repeatedly called for ending certain pediatric shot schedules in the US to become more like Denmark, a nation with universal health coverage and a citizenry roughly the population of Wisconsin’s.

So far public appearances, she has persisted in emphasizing on immunizations – typically the responsibility of Dr. Prasad, director of the FDA’s vaccine center – instead of drug regulation.

Questions Over Background

Høeg has little discernible background in medication creation, regulation or leadership, which has been typical for former heads of the Center for Biologics Evaluation and Research. She has served at the FDA as a senior adviser to the FDA chief and CBER since March.

“She appears not to have the necessary background” for running the drug-regulation department, said Jonathan Howard. “She’s never run a randomized controlled trial. She is not versed in running a major agency. She lacks background in drug approvals.”

Past heads of CBER would “understand regulatory frameworks and the underlying principles of pharmaceutical innovation”, noted Dr. Janet Woodcock. “Objectively, she has not acquired the type of experience that former directors who led the center have had.”

This division has an vast portfolio at the agency, Woodcock pointed out.

“Everybody just pays attention on the new drug program, but the generic drug division authorizes a multitude of generic medications. There’s a biologic copycat branch, non-prescription drug unit and other areas, and all of those have to be managed,” Woodcock explained. “The area you neglect, that is the part that I always told people is going to bite you.”

Additionally, a major leadership aspect to the role, which supervises more than 5,000 employees. “It is a massive administrative position, if you do it right,” Woodcock added.

Response and Contentious Initiatives

In response to concerns about Høeg’s credentials and whether this assignment represents more teamwork among agency officials on vaccines, a spokesperson stated that the “inquiries rely on inaccurate presumptions”.

“Her resume matches the functions of her position,” the representative explained, citing the period Høeg spent advising the FDA commissioner on “medication safety and approval science, including computational safety modeling and shot safety tracking”.

In her interim role, Høeg assumes responsibility for the agency head's new expedited review system, a controversial one-day drug-approval program that reportedly worried her former heads. “How are these therapies being chosen for this fast-track system? Who is making the calls?” Dr. Howard asked. “There is a lot of confidentiality going on at the regulatory body right now.”

Broadly speaking, he said, “the agency looks to be trending towards laxer oversight of all drugs, with the exception of shots.”

Established History on Immunizations

With immunizations, Høeg has a more established, if problematic, history, critics said. She authored a research paper using non-validated volunteer-provided data to estimate the frequency of heart inflammation after Covid vaccination. She advised the Florida surgeon general Dr. Joseph Ladapo, who reportedly have modified findings to indicate COVID-19 vaccines are riskier than they are.

Included in her “policy goals” for the incoming administration encompassed altering guidelines for new vaccines and halting “non-essential” immunizations, she remarked post-election on a online show. At the FDA, Høeg has reportedly suggested preventing teenage boys from obtaining COVID-19 vaccinations.

“She’s an all-around ideologue who begins with her preconceived notions and reverse-engineers to fit the science in a extremely deceptive, untruthful way,” Howard said.

Gaining Influence and a “Push for Payback”

Dr. Høeg became part of other dissenters, {like|